Directional Atherectomy With Antirestenotic Therapy Versus PTA/Supera Stenting for Popliteal Artery Lesions: A Propensity-Matched Analysis

Abstract

Purpose:

This study examines the use and impact of directional atherectomy with antirestenotic therapy (DAART) versus angioplasty plus Supera stent implantation on the outcomes during endovascular treatment of popliteal lesions in clinical practice.

Methods:

Overall 143 consecutive patients (mean age 75.0±12.2 years, 72% male), with isolated atherosclerotic disease of the popliteal artery who underwent endovascular treatment using DAART therapy or percutaneous transluminal angioplasty (PTA)/Supera stenting of the popliteal artery between January 2016 and December 2021 were identified from a retrospectively database. Patient and plaque characteristics were collected. A propensity-score matched, case-control analysis was conducted to balance covariates between the group of patients who underwent DAART and the one treated by PTA/Supera stenting.

Results:

A total of 51 patients (35.7%) showed severe claudication and 92 (64.3%) critical limb ischemia. There was a trend toward longer treated lesions (90.4±81 vs 72.5±5.3 mm, p=0.089) and more chronic total occlusions (60.5% vs 46.8%, p=0.058) in the PTA/Supera stenting group, although not reaching statistically significance. Moderate-to-severe calcification was present in most lesions treated (75.8% of DAART group, 80.2% of PTA/Supera stenting group, and 78.3% of total cohort). Among the 53 case-matched pairs of patients treated with DAART or PTA/Supera stenting, there were no significant differences in short-term outcomes, including rate of technical success (96.2% vs 98.1%, p=0.232), procedural success (88.7% vs 90.1%, p=0.251), distal embolization (1.9% vs 1.9%, p=0.178), dissection (5.7% vs 1.9%, p=0.268), perforation (3.8% vs 5.6%, p=0.163), hospital discharge (1.2±0.1 vs 1.0±0.1, p=0.325), 30 day minor (28.3% vs 32.1%, p=0.264) or major amputation rates (7.5% vs 3.8%, p=0.107), and 30 day mortality (1.9% vs 1.9%, p=0.173). At 1 year, there was no difference in primary patency (73.6% vs 77.4%, p=0.233), primary assisted patency (81.3% vs 84.9%, p=0.167), secondary patency (86.8% vs 92.5%, p=0.094), ipsilateral minor (35.8% vs 39.6%, p=0.472) or major amputation (9.4% vs 7.5%, p=0.186), ankle brachial index improvement (0.32±0.12 vs 0.37±0.37, p=0.401), or mortality (5.7% vs 5.7%, p=0.121) rate between patients who underwent DAART or PTA/Supera stenting for popliteal lesions.

Conclusion:

Twelve-month results following DAART technique or PTA/Supera stenting of atherosclerotic lesions of the popliteal artery are not different, regardless of patient and plaque characteristics.

Clinical Impact

The DAART technique for the treatment of popliteal artery atherosclerotic disease is presented as a “leave nothing behind” strategy with on-year clinical outcomes similar to ATP/Supera stenting.

Keywords

popliteal artery paclitaxel-eluting balloon percutaneous transluminal angioplasty directional atherectomy Supera stent

Get full access to this article

View all access options for this article.

References

Katsanos

Tepe

Tsetis

, et al. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol. 2014;37(3):592–603.

Tzafriri

Garcia-Polite

Zani

, et al. Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis. J Control Release. 2017;264:203–210.

Fanelli

Cannavale

Gazzetti

, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37(4):898–907.

Sixt

Carpio Cancino

Treszl

, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58(3):682–686.

Zeller

Langhoff

Rocha-Singh

, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017;10(9):e004848.

Garcia

Rosenfield

Metzger

, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89:1259–1267.

Armstrong

Jeon-Slaughter

Kahlon

, et al. Comparative outcomes of Supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the XLPAD registry. J Endovasc Ther. 2020;27(1):60–65.

Bishu

Armstrong

EJ.

Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015;11:387–395.

Myint

Schouten

Bourke

, et al. A real-world experience with the supera interwoven nitinol stent in femoropopliteal arteries: midterm patency results and failure analysis. J Endovasc Ther. 2016;23(3):433–441.

10.

Troisi

Saratzis

Katsogridakis

, et al. Different endovascular modalities of treatment for isolated atherosclerotic popliteal artery lesions (EMO-POP) registry. J Vasc Surg. 2023;77:231–240.e4.

11.

Stoner

Calligaro

Chaer

, et al. Reporting standards of the society for vascular surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 2016;64:e1–e21.

12.

Fujihara

Kozuki

Tsubakimoto

, et al. Lumen gain after endovascular therapy in calcified superficial femoral artery occlusive disease assessed by intravascular ultrasound (CODE study). J Endovasc Ther. 2019;26(3):322–330.

13.

Haine

Schmid

Schindewolf

, et al. Comparison between interwoven nitinol and drug eluting stents for endovascular treatment of femoropopliteal artery disease. Eur J Vasc Endovasc Surg. 2019;58:865–873.

14.

Katsanos

Spiliopoulos

Kitrou

, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.

15.

Bontinis

Antonopoulos

Bontinis

, et al. A systematic review and meta-analysis of Supera interwoven nitinol stents for the treatment of infrainguinal peripheral arterial disease. J Cardiovasc Surg (Torino). 2022;63(2):137–145.

16.

McKinsey

Zeller

Rocha-Singh

, et al. DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7(8):923–933.

17.

Zhen

Chang

Wang

, et al. Directional atherectomy with antirestenotic therapy for femoropopliteal artery disease: a systematic review and meta-analysis. J Vasc Interv Radiol. 2019;30(10):1586–1592.

18.

Rocha-Singh

Sachar

DeRubertis

, et al. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: the VIVA REALITY study. Catheter Cardiovasc Interv. 2021;98(3):549–558.

19.

Rastan

McKinsey

Garcia

, et al. One-year outcomes following directional atherectomy of popliteal artery lesions: subgroup analysis of the prospective, multicenter DEFINITIVE LE trial. J Endovasc Ther. 2018;25(1):100–108.

20.

Stavroulakis

Schwindt

Torsello

, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;24(2):181–188.

21.

Sullivan

Zeller

Nakamura

; MIMICS-2 Trial Investigators. Treatment of femoropopliteal lesions with the BioMimics 3D vascular stent system: two-year results from the MIMICS-2 trial. J Endovasc Ther. 2021;28:236–245.

22.

Adams

Shammas

Mangalmurti

, et al. Intravascular lithotripsy for treatment of calcified lower extremity arterial stenosis: initial analysis of the disrupt PAD III study. J Endovasc Ther. 2020;27:473–480.